PO.IM01.05 · 免疫学

在人类T细胞中进行体内全基因组CRISPR筛选以增强针对实体瘤的T细胞疗法

In vivo genome-wide CRISPR screens in human T cells to enhance T cell therapy for solid tumors

海报缩略图:在人类T细胞中进行体内全基因组CRISPR筛选以增强针对实体瘤的T细胞疗法
编号 1532 展板 14 时间 4/20 09:00–12:00 区域 Section 7 主讲 Qi Liu, PhD
分会场 CAR T Cell Targets and TME Reprogramming
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Qi Liu1, Peixin(Amy) Chen1, Esha Urs1, Shimin Zhang1, Maya M. Arce1, Charlotte H. Wang1, Zhongmei Li1, Jin Seo1, Nupura Kale1, Taylor N. LaFlam1, Fanglue Peng1, Eric Shifrut1, Greg Allen2, Justin Eyquem3, Katherine C. Fuh2, Stacie E. Dodgson4, Jason Cyster5, Alexander Marson2, Julia Carnevale1

1UCSF School of Medicine, San Francisco, CA,2UCSF - University of California San Francisco, San Francisco, CA,3University of California, San Francisco, San Francisco, CA,4Gladstone Institute, San Francisco, CA,5University of California, San Francisco, CA

摘要 Abstract

中文摘要
在人类T细胞中进行大规模CRISPR筛选,对于识别能够增强细胞免疫疗法的遗传修饰具有重大前景。然而,许多在实体瘤中调控T细胞性能的遗传调节因子可能无法在体外轻易揭示。在荷瘤小鼠中进行体内筛选具有更高的生理相关性,但历来受限于瘤内T细胞回收率低。在此,我们开发了一种新的模型系统,可从肿瘤中实现显著更高的人类T细胞回收率,从而能够用少量小鼠进行全基因组体内筛选。与匹配的脾脏T细胞相比,该模型中的肿瘤浸润T细胞表现出功能障碍的特征,为筛选肿瘤微环境中T细胞活性的遗传修饰因子创造了理想的背景。利用该平台,我们进行了两次全基因组CRISPR敲除筛选,以识别调控T细胞瘤内丰度和效应功能(如IFN-gamma生成)的基因。瘤内丰度筛选揭示P2RY8-Galpha13 GPCR信号通路是人类T细胞浸润肿瘤的负调控因子。效应功能筛选识别出GNAS(Galphas)——多个感知不同抑制性配体的GPCR下游的核心信号介质——是肿瘤中T细胞功能障碍的关键调控因子。靶向敲除GNAS使T细胞对多种抑制性信号产生抗性,并在多种实体瘤模型中显著改善治疗性能。此外,联合敲除P2RY8(迁移)和GNAS(效应功能)进一步增强了整体肿瘤控制,表明针对不同T细胞表型的遗传修饰可以组合以提高治疗效力。这一灵活且可扩展的体内筛选平台可适配于多种肿瘤模型和混合CRISPR文库,从而助力未来发现使T细胞疗法克服实体瘤所设障碍的遗传策略。
查看英文原文 English abstract
Large-scale CRISPR screening in human T cells holds significant promise for identifying genetic modifications that can enhance cellular immunotherapy. However, many genetic regulators of T cell performance in solid tumors may not be readily revealed in vitro. In vivo screening in tumor-bearing mice offers greater physiological relevance, but has historically been limited by low intratumoral T cell recovery. Here, we developed a new model system that achieves significantly higher human T cell recovery from tumors, enabling genome-wide in vivo screens with small numbers of mice. Tumor-infiltrating T cells in this model exhibit hallmarks of dysfunction compared to matched splenic T cells, creating an ideal context for screening for genetic modifiers of T cell activity in the tumor microenvironment. Using this platform, we performed two genome-wide CRISPR knockout screens to identify genes regulating T cell intratumoral abundance and effector function (e.g., IFN-gamma production). The intratumoral abundance screen uncovered the P2RY8-Galpha13 GPCR signaling pathway as a negative regulator of human T cell infiltration into tumors. The effector function screen identified GNAS (Galphas), a central signaling mediator downstream of multiple GPCRs that sense different suppressive ligands, as a key regulator of T cell dysfunction in tumors. Targeted GNAS knockout rendered T cells resistant to multiple suppressive cues and significantly improved therapeutic performance across diverse solid tumor models. Moreover, combinatorial knockout of P2RY8 (trafficking) and GNAS (effector function) further enhanced overall tumor control, demonstrating that genetic modifications targeting distinct T cell phenotypes can be combined to improve therapeutic potency. This flexible and scalable in vivo screening platform can be adapted to diverse tumor models and pooled CRISPR libraries, enabling future discovery of genetic strategies that equip T cell therapies to overcome barriers imposed by solid tumors.
利益披露 Disclosure
Q. Liu, None.. P. Chen, None.. E. Urs, None.. S. Zhang, None.. M. M. Arce, None.. C. H. Wang, None.. Z. Li, None.. J. Seo, None.. N. Kale, None.. T. N. LaFlam, None.. F. Peng, None.. E. Shifrut, None.. S. E. Dodgson, None.. J. Carnevale, None.

← 返回 AACR 2026 检索